Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Adoptive Cellular Immunotherapy Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Adoptive Cellular Immunotherapy Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Adoptive Cellular Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 TIL
    • 1.4.3 LAK
    • 1.4.4 CAR-T
    • 1.4.5 TCR-T
    • 1.4.6 CIK
    • 1.4.7 NK
    • 1.4.8 DC
    • 1.4.9 Other
  • 1.5 Market by Application
    • 1.5.1 Global Adoptive Cellular Immunotherapy Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Cancer Hospital
    • 1.5.4 Centers for Disease Control and Prevention
    • 1.5.5 Rehabilitation Center
    • 1.5.6 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Adoptive Cellular Immunotherapy Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Adoptive Cellular Immunotherapy Industry
      • 1.6.1.1 Adoptive Cellular Immunotherapy Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Adoptive Cellular Immunotherapy Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Adoptive Cellular Immunotherapy Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Adoptive Cellular Immunotherapy Market Perspective (2015-2026)
  • 2.2 Adoptive Cellular Immunotherapy Growth Trends by Regions
    • 2.2.1 Adoptive Cellular Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Adoptive Cellular Immunotherapy Historic Market Share by Regions (2015-2020)
    • 2.2.3 Adoptive Cellular Immunotherapy Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Adoptive Cellular Immunotherapy Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Adoptive Cellular Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Adoptive Cellular Immunotherapy Players by Market Size
    • 3.1.1 Global Top Adoptive Cellular Immunotherapy Players by Revenue (2015-2020)
    • 3.1.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Adoptive Cellular Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Adoptive Cellular Immunotherapy Market Concentration Ratio
    • 3.2.1 Global Adoptive Cellular Immunotherapy Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Adoptive Cellular Immunotherapy Revenue in 2019
  • 3.3 Adoptive Cellular Immunotherapy Key Players Head office and Area Served
  • 3.4 Key Players Adoptive Cellular Immunotherapy Product Solution and Service
  • 3.5 Date of Enter into Adoptive Cellular Immunotherapy Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Adoptive Cellular Immunotherapy Historic Market Size by Type (2015-2020)
  • 4.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Type (2021-2026)

5 Adoptive Cellular Immunotherapy Breakdown Data by Application (2015-2026)

  • 5.1 Global Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)
  • 5.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 6.2 Adoptive Cellular Immunotherapy Key Players in North America (2019-2020)
  • 6.3 North America Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 6.4 North America Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 7.2 Adoptive Cellular Immunotherapy Key Players in Europe (2019-2020)
  • 7.3 Europe Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 7.4 Europe Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

8 China

  • 8.1 China Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 8.2 Adoptive Cellular Immunotherapy Key Players in China (2019-2020)
  • 8.3 China Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 8.4 China Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 9.2 Adoptive Cellular Immunotherapy Key Players in Japan (2019-2020)
  • 9.3 Japan Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 9.4 Japan Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 10.2 Adoptive Cellular Immunotherapy Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

11 India

  • 11.1 India Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 11.2 Adoptive Cellular Immunotherapy Key Players in India (2019-2020)
  • 11.3 India Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 11.4 India Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Adoptive Cellular Immunotherapy Market Size (2015-2020)
  • 12.2 Adoptive Cellular Immunotherapy Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
  • 12.4 Central & South America Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Amgen Inc
    • 13.1.1 Amgen Inc Company Details
    • 13.1.2 Amgen Inc Business Overview and Its Total Revenue
    • 13.1.3 Amgen Inc Adoptive Cellular Immunotherapy Introduction
    • 13.1.4 Amgen Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020))
    • 13.1.5 Amgen Inc Recent Development
  • 13.2 Autolus Therapeutics Plc
    • 13.2.1 Autolus Therapeutics Plc Company Details
    • 13.2.2 Autolus Therapeutics Plc Business Overview and Its Total Revenue
    • 13.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Introduction
    • 13.2.4 Autolus Therapeutics Plc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.2.5 Autolus Therapeutics Plc Recent Development
  • 13.3 Beijing Immunochina Medical Science & Technology Co Ltd
    • 13.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Company Details
    • 13.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Business Overview and Its Total Revenue
    • 13.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 13.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Development
  • 13.4 Bellicum Pharmaceuticals Inc
    • 13.4.1 Bellicum Pharmaceuticals Inc Company Details
    • 13.4.2 Bellicum Pharmaceuticals Inc Business Overview and Its Total Revenue
    • 13.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Introduction
    • 13.4.4 Bellicum Pharmaceuticals Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.4.5 Bellicum Pharmaceuticals Inc Recent Development
  • 13.5 Bristol-Myers Squibb Co
    • 13.5.1 Bristol-Myers Squibb Co Company Details
    • 13.5.2 Bristol-Myers Squibb Co Business Overview and Its Total Revenue
    • 13.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Introduction
    • 13.5.4 Bristol-Myers Squibb Co Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.5.5 Bristol-Myers Squibb Co Recent Development
  • 13.6 bluebird bio Inc
    • 13.6.1 bluebird bio Inc Company Details
    • 13.6.2 bluebird bio Inc Business Overview and Its Total Revenue
    • 13.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Introduction
    • 13.6.4 bluebird bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.6.5 bluebird bio Inc Recent Development
  • 13.7 CARsgen Therapeutics Ltd
    • 13.7.1 CARsgen Therapeutics Ltd Company Details
    • 13.7.2 CARsgen Therapeutics Ltd Business Overview and Its Total Revenue
    • 13.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Introduction
    • 13.7.4 CARsgen Therapeutics Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.7.5 CARsgen Therapeutics Ltd Recent Development
  • 13.8 Celgene Corp
    • 13.8.1 Celgene Corp Company Details
    • 13.8.2 Celgene Corp Business Overview and Its Total Revenue
    • 13.8.3 Celgene Corp Adoptive Cellular Immunotherapy Introduction
    • 13.8.4 Celgene Corp Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.8.5 Celgene Corp Recent Development
  • 13.9 Cell Medica Ltd
    • 13.9.1 Cell Medica Ltd Company Details
    • 13.9.2 Cell Medica Ltd Business Overview and Its Total Revenue
    • 13.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Introduction
    • 13.9.4 Cell Medica Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.9.5 Cell Medica Ltd Recent Development
  • 13.10 Cellular Biomedicine Group Inc
    • 13.10.1 Cellular Biomedicine Group Inc Company Details
    • 13.10.2 Cellular Biomedicine Group Inc Business Overview and Its Total Revenue
    • 13.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Introduction
    • 13.10.4 Cellular Biomedicine Group Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 13.10.5 Cellular Biomedicine Group Inc Recent Development
  • 13.11 Celularity Inc
    • 10.11.1 Celularity Inc Company Details
    • 10.11.2 Celularity Inc Business Overview and Its Total Revenue
    • 10.11.3 Celularity Inc Adoptive Cellular Immunotherapy Introduction
    • 10.11.4 Celularity Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.11.5 Celularity Inc Recent Development
  • 13.12 Celyad SA
    • 10.12.1 Celyad SA Company Details
    • 10.12.2 Celyad SA Business Overview and Its Total Revenue
    • 10.12.3 Celyad SA Adoptive Cellular Immunotherapy Introduction
    • 10.12.4 Celyad SA Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.12.5 Celyad SA Recent Development
  • 13.13 Daiichi Sankyo Co Ltd
    • 10.13.1 Daiichi Sankyo Co Ltd Company Details
    • 10.13.2 Daiichi Sankyo Co Ltd Business Overview and Its Total Revenue
    • 10.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.13.4 Daiichi Sankyo Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.13.5 Daiichi Sankyo Co Ltd Recent Development
  • 13.14 Fosun Pharmaceutical AG
    • 10.14.1 Fosun Pharmaceutical AG Company Details
    • 10.14.2 Fosun Pharmaceutical AG Business Overview and Its Total Revenue
    • 10.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Introduction
    • 10.14.4 Fosun Pharmaceutical AG Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.14.5 Fosun Pharmaceutical AG Recent Development
  • 13.15 Gilead Sciences Inc
    • 10.15.1 Gilead Sciences Inc Company Details
    • 10.15.2 Gilead Sciences Inc Business Overview and Its Total Revenue
    • 10.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Introduction
    • 10.15.4 Gilead Sciences Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.15.5 Gilead Sciences Inc Recent Development
  • 13.16 Guangzhou Anjie Biomedical Technology Co Ltd
    • 10.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Company Details
    • 10.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Business Overview and Its Total Revenue
    • 10.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Development
  • 13.17 Hangzhou Converd Co Ltd
    • 10.17.1 Hangzhou Converd Co Ltd Company Details
    • 10.17.2 Hangzhou Converd Co Ltd Business Overview and Its Total Revenue
    • 10.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.17.4 Hangzhou Converd Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.17.5 Hangzhou Converd Co Ltd Recent Development
  • 13.18 Hebei Senlang Biotechnology Inc Ltd
    • 10.18.1 Hebei Senlang Biotechnology Inc Ltd Company Details
    • 10.18.2 Hebei Senlang Biotechnology Inc Ltd Business Overview and Its Total Revenue
    • 10.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.18.4 Hebei Senlang Biotechnology Inc Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Development
  • 13.19 HRAIN Biotechnology Co Ltd
    • 10.19.1 HRAIN Biotechnology Co Ltd Company Details
    • 10.19.2 HRAIN Biotechnology Co Ltd Business Overview and Its Total Revenue
    • 10.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.19.4 HRAIN Biotechnology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.19.5 HRAIN Biotechnology Co Ltd Recent Development
  • 13.20 Juno Therapeutics Inc
    • 10.20.1 Juno Therapeutics Inc Company Details
    • 10.20.2 Juno Therapeutics Inc Business Overview and Its Total Revenue
    • 10.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
    • 10.20.4 Juno Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.20.5 Juno Therapeutics Inc Recent Development
  • 13.21 Kite Pharma Inc
    • 10.21.1 Kite Pharma Inc Company Details
    • 10.21.2 Kite Pharma Inc Business Overview and Its Total Revenue
    • 10.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Introduction
    • 10.21.4 Kite Pharma Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.21.5 Kite Pharma Inc Recent Development
  • 13.22 Nanjing Legend Biotech Co Ltd
    • 10.22.1 Nanjing Legend Biotech Co Ltd Company Details
    • 10.22.2 Nanjing Legend Biotech Co Ltd Business Overview and Its Total Revenue
    • 10.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.22.4 Nanjing Legend Biotech Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.22.5 Nanjing Legend Biotech Co Ltd Recent Development
  • 13.23 NantKwest Inc
    • 10.23.1 NantKwest Inc Company Details
    • 10.23.2 NantKwest Inc Business Overview and Its Total Revenue
    • 10.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Introduction
    • 10.23.4 NantKwest Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.23.5 NantKwest Inc Recent Development
  • 13.24 Nkarta Inc
    • 10.24.1 Nkarta Inc Company Details
    • 10.24.2 Nkarta Inc Business Overview and Its Total Revenue
    • 10.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Introduction
    • 10.24.4 Nkarta Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.24.5 Nkarta Inc Recent Development
  • 13.25 Novartis AG
    • 10.25.1 Novartis AG Company Details
    • 10.25.2 Novartis AG Business Overview and Its Total Revenue
    • 10.25.3 Novartis AG Adoptive Cellular Immunotherapy Introduction
    • 10.25.4 Novartis AG Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.25.5 Novartis AG Recent Development
  • 13.26 Ono Pharmaceutical Co Ltd
    • 10.26.1 Ono Pharmaceutical Co Ltd Company Details
    • 10.26.2 Ono Pharmaceutical Co Ltd Business Overview and Its Total Revenue
    • 10.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.26.4 Ono Pharmaceutical Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.26.5 Ono Pharmaceutical Co Ltd Recent Development
  • 13.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
    • 10.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details
    • 10.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Business Overview and Its Total Revenue
    • 10.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
    • 10.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Development
  • 13.28 Sorrento Therapeutics Inc
    • 10.28.1 Sorrento Therapeutics Inc Company Details
    • 10.28.2 Sorrento Therapeutics Inc Business Overview and Its Total Revenue
    • 10.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
    • 10.28.4 Sorrento Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.28.5 Sorrento Therapeutics Inc Recent Development
  • 13.29 Takara Bio Inc
    • 10.29.1 Takara Bio Inc Company Details
    • 10.29.2 Takara Bio Inc Business Overview and Its Total Revenue
    • 10.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Introduction
    • 10.29.4 Takara Bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
    • 10.29.5 Takara Bio Inc Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Adoptive Cellular Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Adoptive Cellular Immunotherapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Amgen Inc
    Autolus Therapeutics Plc
    Beijing Immunochina Medical Science & Technology Co Ltd
    Bellicum Pharmaceuticals Inc
    Bristol-Myers Squibb Co
    bluebird bio Inc
    CARsgen Therapeutics Ltd
    Celgene Corp
    Cell Medica Ltd
    Cellular Biomedicine Group Inc
    Celularity Inc
    Celyad SA
    Daiichi Sankyo Co Ltd
    Fosun Pharmaceutical AG
    Gilead Sciences Inc
    Guangzhou Anjie Biomedical Technology Co Ltd
    Hangzhou Converd Co Ltd
    Hebei Senlang Biotechnology Inc Ltd
    HRAIN Biotechnology Co Ltd
    Juno Therapeutics Inc
    Kite Pharma Inc
    Nanjing Legend Biotech Co Ltd
    NantKwest Inc
    Nkarta Inc
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
    Sorrento Therapeutics Inc
    Takara Bio Inc

    Market segment by Type, the product can be split into
    TIL
    LAK
    CAR-T
    TCR-T
    CIK
    NK
    DC
    Other
    Market segment by Application, split into
    Hospital
    Cancer Hospital
    Centers for Disease Control and Prevention
    Rehabilitation Center
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Adoptive Cellular Immunotherapy status, future forecast, growth opportunity, key market and key players.
    To present the Adoptive Cellular Immunotherapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Adoptive Cellular Immunotherapy are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now